Fluicell AB (publ) (STO:FLUI)
Sweden · Delayed Price · Currency is SEK 31.40
+0.10 (0.32%)
Sep 4, 2026, 11:24 AM CET
Fluicell AB Revenue
Fluicell AB had revenue of 8.70M SEK in the quarter ending June 30, 2026, with 145.72% growth. This brings the company's revenue in the last twelve months to 25.51M, up 344.50% year-over-year. In the year 2025, Fluicell AB had annual revenue of 15.51M with 46.79% growth.
Revenue (ttm)
25.51M
Revenue Growth
+344.50%
P/S Ratio
1.94
Revenue / Employee
2.02M
Employees
11
Market Cap
43.00M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.51M | 4.94M | 46.79% |
| Dec 31, 2024 | 10.57M | 5.94M | 128.16% |
| Dec 31, 2023 | 4.63M | -2.41M | -34.24% |
| Dec 31, 2022 | 7.04M | 3.05M | 76.49% |
| Dec 31, 2021 | 3.99M | -880.00K | -18.07% |
| Dec 31, 2020 | 4.87M | 2.28M | 87.96% |
| Dec 31, 2019 | 2.59M | 1.37M | 111.34% |
| Dec 31, 2018 | 1.23M | 150.00K | 13.94% |
| Dec 31, 2017 | 1.08M | -1.58M | -59.43% |
| Dec 31, 2016 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanologica AB | 136.17M |
| ExpreS2ion Biotech Holding AB | 24.25M |
| Biovica International AB | 13.49M |
| AcouSort AB | 9.31M |
| OncoZenge AB | 5.97M |
| Spago Nanomedical AB | 3.81M |
| Alligator Bioscience AB | 681.00K |
| Pila Pharma AB | 275.74K |
Fluicell AB News
- 7 days ago - Fluicell AB Quarterly report: Q2 2026 - Filings
- 3 months ago - Fluicell AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Fluicell AB Annual report: Q4 2025 - Filings
- 6 months ago - Fluicell AB Quarterly report: Q4 2025 - Filings
- 9 months ago - Fluicell AB Quarterly report: Q3 2025 - Filings